ASCO: Lilly exec points to ‘nutty’ 100% response rate for in vivo CAR-T as justifying Kelonia buyout

Kelonia Therapeutics has shared the largest slice of data yet for an in vivo CAR-T, helping to justify the $3.2 billion price tag that Eli Lilly recently paid t...